The treatment of chronic myelogenous leukaemia (CML) by inhibition of the oncogenic protein kinase BCR-ABL using small-molecule drugs such as imatinib, dasatinib, or bosutinib has been highly effective. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.